This contract award provides the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) with a $13.4 billion Indefinite Delivery Contract (IDC) to acquire medical countermeasures (MCMs) such as vaccines and adjuvants for pandemic preparedness and response. The prime contractor, Seqirus Inc., a division of the global biotechnology company CSL Seqirus, operates a manufacturing facility in Holly Springs, North Carolina and has extensive expertise in developing and producing vaccines, particularly for influenza and emerging infectious diseases.
Under this IDC, HHS ASPR has issued multiple firm fixed-price delivery orders with Seqirus, totaling over $116 million to date. These orders cover a wide range of services including vaccine production, antigen procurement, clinical research, and stockpile maintenance. The contract does not have any set-aside designations, reflecting Seqirus' status as a leading provider of MCMs to the federal government. The overall period of performance runs from February 2022 through February 2026, with the possibility of extension through February 2027.
Generated 1/22/25, 9:06 AM